The BIOAF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOAF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BIOAF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BIOAF Detailed Price Forecast - CNN Money||View BIOAF Detailed Summary - Google Finance|
|View BIOAF Detailed Summary - Yahoo! Finance||View BIOAF Stock Research & Analysis - Zacks.com|
|View BIOAF Trends & Analysis - Trade-Ideas||View BIOAF Major Holders - Barrons|
|View BIOAF Call Transcripts - NASDAQ||View BIOAF Breaking News & Analysis - Seeking Alpha|
|View BIOAF Annual Report - CompanySpotlight.com||View BIOAF OTC Short Report - OTCShortReport.com|
|View BIOAF Fundamentals - TradeKing||View BIOAF SEC Filings - Bar Chart|
|View Historical Prices for BIOAF - The WSJ||View Performance/Total Return for BIOAF - Morningstar|
|View the Analyst Estimates for BIOAF - MarketWatch||View the Earnings History for BIOAF - CNBC|
|View the BIOAF Earnings - StockMarketWatch||View BIOAF Buy or Sell Recommendations - MacroAxis|
|View the BIOAF Bullish Patterns - American Bulls||View BIOAF Short Pain Metrics - ShortPainBot.com|
|View BIOAF Stock Mentions - StockTwits||View BIOAF Stock Mentions - PennyStockTweets|
|View BIOAF Stock Mentions - Twitter||View BIOAF Investment Forum News - Investor Hub|
|View BIOAF Stock Mentions - Yahoo! Message Board||View BIOAF Stock Mentions - Seeking Alpha|
|View Insider Transactions for BIOAF - SECform4.com||View Insider Transactions for BIOAF - Insider Cow|
|View BIOAF Major Holdings Summary - CNBC||View Insider Disclosure for BIOAF - OTC Markets|
|View Insider Transactions for BIOAF - Yahoo! Finance||View Institutional Holdings for BIOAF - NASDAQ|
|View BIOAF Stock Insight & Charts - FinViz.com||View BIOAF Investment Charts - StockCharts.com|
|View BIOAF Stock Overview & Charts - BarChart||View BIOAF User Generated Charts - Trading View|
Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer
Posted on Monday March 11, 2019
TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that its board of directors has appointed Dr. Deborah A. Rathjen as president and chief executive officer. Dr. Rathjen, who is a member of the board of directors and has served as executive chair since December 10, 2018, replaces Dr. Mark Day, who has left the company, effective immediately.
BiOasis: Fiscal 3Q Earnings Snapshot
Posted on Wednesday January 30, 2019
The Guilford, Connecticut-based company said it had a loss of less than 1 cent on a per-share basis. The biotech drug developer posted revenue of $926,000 in the period. The company's shares closed at ...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018
Posted on Tuesday January 29, 2019
BIOASIS TECHNOLOGIES INC. , a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financial statements and management’s discussion ...
Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer
Posted on Wednesday January 09, 2019
OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Christine Antalik as chief financial officer.